Two studies presented at EADV 2026 highlight misinformation and dermatologic complications linked to viral skincare routines on social media.
|Articles|July 28, 2014
Prohibited product ingredients at a glance
Food and Drug Administration regulations specifically prohibit or restrict use of certain ingredients in cosmetics.
Advertisement
Regulations specifically prohibit or restrict use of these ingredients in cosmetics, according to the Food and Drug Administration:
- Bithionol. May cause photocontact sensitization.
- Chlorofluorocarbon propellants. Used in cosmetic aerosol products and prohibited.
- Chloroform. Prohibited in cosmetic products because of animal carcinogenicity and for being a likely hazard to human health.
- Halogenated salicylanilides (di-, tri-, metabromsalan and tetrachlorosalicylanilide). Also might cause photocontact sensitization.
- Methylene chloride. Prohibited for animal carcinogenicity and as a likely hazard to human health.
- Vinyl chloride. A carcinogen prohibited as an ingredient of aerosol products.
- Zirconium-containing complexes. In aerosol cosmetic products, these are prohibited because of their toxic effect on lungs.
- Prohibited cattle materials. To protect against mad cow disease.
More articles in our package on OTC product ingredients:
Advertisement
Related to this article
Can at-home dermarollers give the same results as in-office microneedling or is that just a myth? Read more about the latest social media trend and learn how to counsel your patients in the clinic.
Find out what skin care products and aesthetic innovations clinicians are recommending to patients for the month of September.
Though convenient, SPF-infused cosmetics rarely deliver their labeled protection level in real-world use, underscoring the continued need for a dedicated broad-spectrum sunscreen as the foundation of any routine.
A new report from the National Eczema Association (NEA) found systemic corticosteroids were filled more often than dupilumab, and 13% of Americans live in counties without a dermatology or allergy/immunology practitioner.
Real-world EADV 2026 data suggest autonomous AI could increase dermatology capacity while maintaining high sensitivity for invasive skin cancers.
Up to 72% of tulisokibart-treated patients achieved HiSCR50 at week 16 vs 35% with placebo, the first positive phase 2 anti-TL1A data in dermatology.
Treatment success reached 56.7% and total lesions fell 71.8% with up to 52 weeks of oral denifanstat, with no adverse event-related discontinuations.
Advertisement
Advertisement
Trending on Dermatology Times
1
Daxdilimab Improves Disease Activity in Treatment-Refractory Discoid Lupus in Phase 2 Trial
2
Late Breaking: Zumilokibart Meets Primary End Point in Phase 2 Atopic Dermatitis Trial
3
Nearly 95% of Viral Korean Skincare TikTok Videos Contain Misleading Claims
4
Nemolizumab Sustains Atopic Dermatitis Responses Through 3 Years in ARCADIA
5